The Science is obviously brilliant6 Mar 2024 09:20
My take is the Science for Pre|CISION is quite obvioisly brilliant so far. Maybe not As paradigm shifting but good enough to hopefully show even more efficacy in P2.
The issue with Avacta is operational. Comms borderline incomprehensible and plans constantly changing to the extent where you give up with timelines.
If Avacta can sort the operational side out, I am confident the market cap will rise significantly from here.
RE: I’m voting for Alistair as this is going to be BIG6 Mar 2024 09:06
Pjt, that's a brilliant post
Avacta really need to challenged on the diagnostics purchases. It's forgivable for a blue chip company to buy and reliase it was a mistake as they can soak it up.
But for Avacta to use significant bond funds on dx when their main asset is tx is just wrong.
There has to be more to this than we will ever find out. Cso leaves, cdo leaves. Look for a new cdo and doesn't happen, interim brouhht in but turns into r and d. Dose expansion removed., then re added.
It's just bonkers to think Avacta was at 135 in December. The CEO comes out with 'we are at the beginning of the value curve'. To me that says here we are and we will now start to ge rate some real worth in thos company. That statement doesn't imply over valued.
Only for a couple of months later to do a 50p placing. Either he was being disingenuous or he vastly misread the market. I probably suspect the latter.
I for one am pleased that that existing holders didn't take up the full allocation as this shows the level of trust that now sits with Avacta. Whilst, in the knowledge they raised plenty of money from the firm placing so are in a position to hopefully monetise precision